Becton, Dickinson and Company (BDX)

FairStock Score: 47/100 — MIXED

Key Financials

Strengths

• Diversified end-market exposure across hospital systems, diagnostic labs, pharmaceutical manufacturers, and life sciences researchers
• Consistent free cash flow generation of $3.1B annually demonstrates operational stability
• Low beta of 0.31 reflects defensive business model resistant to economic cycles
• Essential products with recurring revenue streams create predictable cash flows
• Scale advantages with 70,000 employees providing manufacturing and distribution efficiency

Concerns

• Severely overvalued at 25.18 P/E with negative 223% margin of safety versus Graham Number of $51.74
• Deteriorating financial quality evidenced by Piotroski F-Score of 4/9 and Altman Z-Score of 1.80 in distress zone
• Alarmingly high EV/EBITDA of 68.4x suggests market irrationality or hidden deterioration
• Poor capital returns with ROE of 6.96% and ROCE of 4.08% despite quality business positioning
• Minimal FCF yield of 0.9% provides inadequate compensation for equity risk

AI Analysis

Becton, Dickinson presents a paradox that troubles me. On the surface, we have a quality business—a 70,000-person enterprise with deep moats in medical devices serving hospitals, labs, and pharmaceutical companies worldwide. The low beta of 0.31 confirms its defensive nature. Free cash flow of $3.1B annually is respectable for a $60.5B market cap. However, the financial metrics scream overvaluation and deteriorating fundamentals. At 25.18 times earnings with a Graham Number of just $51.74, we face a negative margin of safety of -223%. This is deeply troubling from a value perspective. The Piotroski F-Score of 4/9 suggests declining financial quality. Most alarming: the EV/EBITDA ratio of 68.4x is astronomical—I've rarely seen such extremes outside of speculative bubbles. The ROE of 6.96% and ROCE of 4.08% are mediocre at best, indicating poor capital efficiency despite a quality business. The Altman Z-Score of 1.80 sits in the distress zone, suggesting potential solvency concerns. With a debt-to-equity of 0.77, leverage is meaningful. The latest quarter shows 7.27% net margin on $5.3B revenue—acceptable but uninspiring. This company may possess competitive advantages in its niches, but I cannot justify the price. A 1% FCF yield on an already expensive valuation offers minimal margin of safety. I would require BDX to trade near $50-60 before considering it a worthwhile investment, representing a 65-70% discount from current levels.

Bull Case

BDX operates in essential healthcare markets with structural growth tailwinds from aging demographics and increased diagnostic testing globally. The company's diversified portfolio across medical devices, diagnostic systems, and biopharmaceutical solutions positions it to benefit from secular healthcare spending increases. Strong FCF generation supports dividend sustainability and potential acquisitions.

Bear Case

The valuation is indefensible at current levels with negative margin of safety and EV/EBITDA exceeding 68x. Deteriorating financial quality metrics (F-Score 4/9, Z-Score 1.80) combined with weak capital efficiency (ROCE 4%) suggest structural challenges ahead. A market correction could see BDX trade 40-50% lower.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer